Recent lawsuits target not only wastewater dischargers but also entities involved in biosolids processing and marketing, emphasizing the importance of legal preparedness.
AI companies or those which offer an AI product need to assess their potential products liability-based exposure and work with counsel to explore potential risks and defenses.
The editorial advisory boards provide feedback on Law360's coverage and expert insight on how best to shape future coverage.
Joe Altieri has conducted numerous depositions, including of plaintiffs and their treating physicians in multimillion dollar products liability litigation.
The rapid expansion of state laws governing the sale of consumer goods containing PFAS poses compliance challenges and litigation risks for multi-state retail chains, internet retailers, and manufacturers.
This case warrants close monitoring because the effect of EPA’s rescission of the 2009 Endangerment Finding and the subsequent repeal of the greenhouse gas emission standards that were born of it will surely be tested in courts for years to come.
While the new rule is not yet final, it is clear that regulators are revisiting standards and risk assessments related to ethylene oxide, which could markedly impact facility operations and litigation strategy. Companies with actual or potential EtO litigation exposure should keep abreast of this shifting environmental regulatory landscape.
The case demonstrates why defendants must carefully assess the bases and potential outcomes of removing a case to federal court based on the theory that another defendant was improperly joined.
The brief cautions that without a Supreme Court ruling, “litigants will continue to face uncertainty in how Rule 702 should be applied, admissibility standards that vary by circuit, and the same wayward decisions that necessitated the rule’s amendment.”
Hollingsworth LLP’s cert petition focuses on the Second Circuit’s erroneous application of the effective vindication exception to the Federal Arbitration Act.
The second Trump administration appears to be changing the FDA approval landscape and new opportunities and pitfalls abound for defendants seeking to establish the all-powerful preemption defense.
The firm has proudly contributed to this publication since 2017 and will continue to monitor impactful class action decisions for the 2027 edition.
